Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.

Patient preference and adherence

Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, Shah H.
PMID: 21845037
Patient Prefer Adherence. 2011;5:375-88. doi: 10.2147/PPA.S19991. Epub 2011 Jul 26.

INTRODUCTION: Adherence to long-acting bronchodilator therapy for management of chronic obstructive pulmonary disease (COPD) is a critical clinical and cost issue. Low adherence is associated with relatively higher exacerbation rates and illness burden.PURPOSE: To compare adherence between patients with...

Cite
Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2011;5:375-88doi: 10.2147/PPA.S19991.
Halpern, R., Baker, C. L., Su, J., Woodruff, K. B., Paulose-Ram, R., Porter, V., & Shah, H. (2011). Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient preference and adherence, 5375-88. https://doi.org/10.2147/PPA.S19991
Halpern, Rachel, et al. "Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease." Patient preference and adherence vol. 5 (2011): 375-88. doi: https://doi.org/10.2147/PPA.S19991
Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, Shah H. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2011;5:375-88. doi: 10.2147/PPA.S19991. Epub 2011 Jul 26. PMID: 21845037; PMCID: PMC3150166.
Copy Download .nbib Format: NLM
Novel 8-heterocyclyl xanthine derivatives in drug development - an update.

Expert opinion on drug discovery

Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D.
PMID: 23496127
Expert Opin Drug Discov. 2007 Sep;2(9):1161-83. doi: 10.1517/17460441.2.9.1161.

Naturally occurring methyl xanthines, especially caffeine and theophylline, have been widely investigated for their pharmacological properties as cognition enhancers, bronchodilator agents and mild diuretics. The xanthine core (3,7-dihydro-1H-purine-2,6-dione) has been largely manipulated in the search for selective ligands for...

Cite
Baraldi PG, Fruttarolo F, Tabrizi MA, et al. Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert Opin Drug Discov. 2007;2(9):1161-83doi: 10.1517/17460441.2.9.1161.
Baraldi, P. G., Fruttarolo, F., Tabrizi, M. A., Romagnoli, R., & Preti, D. (2007). Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert opinion on drug discovery, 2(9), 1161-83. https://doi.org/10.1517/17460441.2.9.1161
Baraldi, Pier G, et al. "Novel 8-heterocyclyl xanthine derivatives in drug development - an update." Expert opinion on drug discovery vol. 2,9 (2007): 1161-83. doi: https://doi.org/10.1517/17460441.2.9.1161
Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D. Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert Opin Drug Discov. 2007 Sep;2(9):1161-83. doi: 10.1517/17460441.2.9.1161. PMID: 23496127.
Copy Download .nbib Format: NLM
Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment.

Journal of clinical medicine

Cheng SL.
PMID: 34208599
J Clin Med. 2021 Jun 16;10(12). doi: 10.3390/jcm10122649.

The effectiveness and safety of fixed dual long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) patients have been well established; however, there is a paucity of clinical effectiveness comparison in patients with COPD treatment. The aim of the current...

Cite
Cheng SL. Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment. J Clin Med. 2021;10(12)doi: 10.3390/jcm10122649.
Cheng, S. L. (2021). Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment. Journal of clinical medicine, 10(12), . https://doi.org/10.3390/jcm10122649
Cheng, Shih-Lung. "Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment." Journal of clinical medicine vol. 10,12 (2021). doi: https://doi.org/10.3390/jcm10122649
Cheng SL. Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment. J Clin Med. 2021 Jun 16;10(12). doi: 10.3390/jcm10122649. PMID: 34208599; PMCID: PMC8235085.
Copy Download .nbib Format: NLM
Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction.

Therapeutic advances in chronic disease

Celi A, Latorre M, Paggiaro P, Pistelli R.
PMID: 34035887
Ther Adv Chronic Dis. 2021 May 13;14:20406223211014028. doi: 10.1177/20406223211014028. eCollection 2021.

Chronic obstructive pulmonary disease (COPD) has a 3-year mortality rate up to 37%, 2-6 times higher than the general population. We present evidence supporting pharmacological therapies to improve patient life expectancy, focusing on inhaled corticosteroids (ICSs) combined with long-acting...

Cite
Celi A, Latorre M, Paggiaro P, et al. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Ther Adv Chronic Dis. 2021;14:20406223211014028doi: 10.1177/20406223211014028.
Celi, A., Latorre, M., Paggiaro, P., & Pistelli, R. (2021). Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Therapeutic advances in chronic disease, 1420406223211014028. https://doi.org/10.1177/20406223211014028
Celi, Alessandro, et al. "Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction." Therapeutic advances in chronic disease vol. 14 (2021): 20406223211014028. doi: https://doi.org/10.1177/20406223211014028
Celi A, Latorre M, Paggiaro P, Pistelli R. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Ther Adv Chronic Dis. 2021 May 13;14:20406223211014028. doi: 10.1177/20406223211014028. eCollection 2021. PMID: 34035887; PMCID: PMC8127735.
Copy Download .nbib Format: NLM
A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation.

Lung India : official organ of Indian Chest Society

Salvi SS, Vaidya AJ, Kodgule RR, Gogtay JA.
PMID: 27185990
Lung India. 2016 May-Jun;33(3):272-7. doi: 10.4103/0970-2113.180803.

CONTEXT: The combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) is widely used in the treatment of moderate-to-severe asthma uncontrolled by ICS alone.AIMS: To evaluate the efficacy and safety of a new ICS-LABA combination inhaler containing Formoterol (F)...

Cite
Salvi SS, Vaidya AJ, Kodgule RR, et al. A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation. Lung India. 2016;33(3):272-7doi: 10.4103/0970-2113.180803.
Salvi, S. S., Vaidya, A. J., Kodgule, R. R., & Gogtay, J. A. (2016). A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation. Lung India : official organ of Indian Chest Society, 33(3), 272-7. https://doi.org/10.4103/0970-2113.180803
Salvi, Sundeep S, et al. "A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation." Lung India : official organ of Indian Chest Society vol. 33,3 (2016): 272-7. doi: https://doi.org/10.4103/0970-2113.180803
Salvi SS, Vaidya AJ, Kodgule RR, Gogtay JA. A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation. Lung India. 2016 May-Jun;33(3):272-7. doi: 10.4103/0970-2113.180803. PMID: 27185990; PMCID: PMC4857562.
Copy Download .nbib Format: NLM
Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities.

Paediatrics & child health

Kovesi T, Giles BL, Pasterkamp H.
PMID: 23904776
Paediatr Child Health. 2012 Aug;17(7):e46-64.

Asthma is a serious health problem for First Nations and Inuit children. In children younger than one year of age, asthma needs to be distinguished from viral bronchiolitis, which is unusually common in Canadian Aboriginal children. In children younger...

Cite
Kovesi T, Giles BL, Pasterkamp H. Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities. Paediatr Child Health. 2012;17(7):e46-64
Kovesi, T., Giles, B. L., & Pasterkamp, H. (2012). Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities. Paediatrics & child health, 17(7), e46-64.
Kovesi, Tom, et al. "Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities." Paediatrics & child health vol. 17,7 (2012): e46-64.
Kovesi T, Giles BL, Pasterkamp H. Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities. Paediatr Child Health. 2012 Aug;17(7):e46-64. French. PMID: 23904776; PMCID: PMC3448548.
Copy Download .nbib Format: NLM
Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study.

Pulmonary therapy

Hahn B, Stanford RH, Hunter AG, White J, Essoi B, Ray R.
PMID: 32026410
Pulm Ther. 2019 Dec;5(2):179-190. doi: 10.1007/s41030-019-00098-1. Epub 2019 Aug 07.

INTRODUCTION: Many patients with chronic obstructive pulmonary disease (COPD) prescribed long-acting muscarinic antagonist (LAMA) monotherapy remain symptomatic. This multivariable analysis of a previously reported claims-linked, cross-sectional survey assessed symptom burden measured by the COPD assessment test (CAT) in patients...

Cite
Hahn B, Stanford RH, Hunter AG, et al. Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study. Pulm Ther. 2019;5(2):179-190doi: 10.1007/s41030-019-00098-1.
Hahn, B., Stanford, R. H., Hunter, A. G., White, J., Essoi, B., & Ray, R. (2019). Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study. Pulmonary therapy, 5(2), 179-190. https://doi.org/10.1007/s41030-019-00098-1
Hahn, Beth, et al. "Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study." Pulmonary therapy vol. 5,2 (2019): 179-190. doi: https://doi.org/10.1007/s41030-019-00098-1
Hahn B, Stanford RH, Hunter AG, White J, Essoi B, Ray R. Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study. Pulm Ther. 2019 Dec;5(2):179-190. doi: 10.1007/s41030-019-00098-1. Epub 2019 Aug 07. PMID: 32026410; PMCID: PMC6967173.
Copy Download .nbib Format: NLM
Paediatrics: how to manage acute asthma exacerbations.

Drugs in context

Leung JS.
PMID: 34113386
Drugs Context. 2021 May 26;10. doi: 10.7573/dic.2020-12-7. eCollection 2021.

BACKGROUND: Asthma is the most common chronic disease of childhood and a major source of childhood health burden worldwide. These burdens are particularly marked when children experience characteristic 'symptom flare-ups' or acute asthma exacerbations (AAEs). AAE are associated with...

Cite
Leung JS. Paediatrics: how to manage acute asthma exacerbations. Drugs Context. 2021;10doi: 10.7573/dic.2020-12-7.
Leung, J. S. (2021). Paediatrics: how to manage acute asthma exacerbations. Drugs in context, 10. https://doi.org/10.7573/dic.2020-12-7
Leung, James S. "Paediatrics: how to manage acute asthma exacerbations." Drugs in context vol. 10 (2021). doi: https://doi.org/10.7573/dic.2020-12-7
Leung JS. Paediatrics: how to manage acute asthma exacerbations. Drugs Context. 2021 May 26;10. doi: 10.7573/dic.2020-12-7. eCollection 2021. PMID: 34113386; PMCID: PMC8166724.
Copy Download .nbib Format: NLM
Spirometry and Bronchodilator Test.

Tuberculosis and respiratory diseases

Sim YS, Lee JH, Lee WY, Suh DI, Oh YM, Yoon JS, Lee JH, Cho JH, Kwon CS, Chang JH.
PMID: 28416951
Tuberc Respir Dis (Seoul). 2017 Apr;80(2):105-112. doi: 10.4046/trd.2017.80.2.105. Epub 2017 Mar 31.

Spirometry is a physiological test for assessing the functional aspect of the lungs using an objective indicator to measure the maximum amount of air that a patient can inhale and exhale. Acceptable spirometry testing needs to be conducted three...

Cite
Sim YS, Lee JH, Lee WY, et al. Spirometry and Bronchodilator Test. Tuberc Respir Dis (Seoul). 2017;80(2):105-112doi: 10.4046/trd.2017.80.2.105.
Sim, Y. S., Lee, J. H., Lee, W. Y., Suh, D. I., Oh, Y. M., Yoon, J. S., Lee, J. H., Cho, J. H., Kwon, C. S., & Chang, J. H. (2017). Spirometry and Bronchodilator Test. Tuberculosis and respiratory diseases, 80(2), 105-112. https://doi.org/10.4046/trd.2017.80.2.105
Sim, Yun Su, et al. "Spirometry and Bronchodilator Test." Tuberculosis and respiratory diseases vol. 80,2 (2017): 105-112. doi: https://doi.org/10.4046/trd.2017.80.2.105
Sim YS, Lee JH, Lee WY, Suh DI, Oh YM, Yoon JS, Lee JH, Cho JH, Kwon CS, Chang JH. Spirometry and Bronchodilator Test. Tuberc Respir Dis (Seoul). 2017 Apr;80(2):105-112. doi: 10.4046/trd.2017.80.2.105. Epub 2017 Mar 31. PMID: 28416951; PMCID: PMC5392482.
Copy Download .nbib Format: NLM
Serum magnesium levels and its correlation with level of control in patients with asthma: A hospital-based, cross-sectional, prospective study.

Lung India : official organ of Indian Chest Society

Daliparty VM, Manu MK, Mohapatra AK.
PMID: 30168460
Lung India. 2018 Sep-Oct;35(5):407-410. doi: 10.4103/lungindia.lungindia_55_18.

CONTEXT: Magnesium (Mg) is an intracellular cation which takes part in various functions including smooth muscle contractility. Studies have shown that serum Mg level has no significant effect on asthma severity. There are only sparse data on the effect...

Cite
Daliparty VM, Manu MK, Mohapatra AK. Serum magnesium levels and its correlation with level of control in patients with asthma: A hospital-based, cross-sectional, prospective study. Lung India. 2018;35(5):407-410doi: 10.4103/lungindia.lungindia_55_18.
Daliparty, V. M., Manu, M. K., & Mohapatra, A. K. (2018). Serum magnesium levels and its correlation with level of control in patients with asthma: A hospital-based, cross-sectional, prospective study. Lung India : official organ of Indian Chest Society, 35(5), 407-410. https://doi.org/10.4103/lungindia.lungindia_55_18
Daliparty, Vasudev Malik, et al. "Serum magnesium levels and its correlation with level of control in patients with asthma: A hospital-based, cross-sectional, prospective study." Lung India : official organ of Indian Chest Society vol. 35,5 (2018): 407-410. doi: https://doi.org/10.4103/lungindia.lungindia_55_18
Daliparty VM, Manu MK, Mohapatra AK. Serum magnesium levels and its correlation with level of control in patients with asthma: A hospital-based, cross-sectional, prospective study. Lung India. 2018 Sep-Oct;35(5):407-410. doi: 10.4103/lungindia.lungindia_55_18. PMID: 30168460; PMCID: PMC6120318.
Copy Download .nbib Format: NLM
Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea.

Tuberculosis and respiratory diseases

Yum HK, Kim HR, Chang YS, Shin KC, Kim S, Oh YM.
PMID: 28119747
Tuberc Respir Dis (Seoul). 2017 Jan;80(1):52-59. doi: 10.4046/trd.2017.80.1.52. Epub 2016 Dec 30.

BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting βMETHODS: This was an open-label, observational, prospective study in which COPD patients, who were newly prescribed with indacaterol (150 or 300 µg), were evaluated for 12 or 24 weeks. Safety was assessed...

Cite
Yum HK, Kim HR, Chang YS, et al. Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Tuberc Respir Dis (Seoul). 2016;80(1):52-59doi: 10.4046/trd.2017.80.1.52.
Yum, H. K., Kim, H. R., Chang, Y. S., Shin, K. C., Kim, S., & Oh, Y. M. (2017). Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Tuberculosis and respiratory diseases, 80(1), 52-59. https://doi.org/10.4046/trd.2017.80.1.52
Yum, Ho-Kee, et al. "Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea." Tuberculosis and respiratory diseases vol. 80,1 (2017): 52-59. doi: https://doi.org/10.4046/trd.2017.80.1.52
Yum HK, Kim HR, Chang YS, Shin KC, Kim S, Oh YM. Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Tuberc Respir Dis (Seoul). 2017 Jan;80(1):52-59. doi: 10.4046/trd.2017.80.1.52. Epub 2016 Dec 30. PMID: 28119747; PMCID: PMC5256353.
Copy Download .nbib Format: NLM
Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study.

Pulmonary therapy

Hahn B, Stanford RH, Goolsby Hunter A, Essoi B, White J, Ray R.
PMID: 32026428
Pulm Ther. 2019 Jun;5(1):69-80. doi: 10.1007/s41030-019-0091-0. Epub 2019 Apr 01.

INTRODUCTION: Symptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom burden and HCRU among a prevalent population of COPD...

Cite
Hahn B, Stanford RH, Goolsby Hunter A, et al. Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. Pulm Ther. 2019;5(1):69-80doi: 10.1007/s41030-019-0091-0.
Hahn, B., Stanford, R. H., Goolsby Hunter, A., Essoi, B., White, J., & Ray, R. (2019). Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. Pulmonary therapy, 5(1), 69-80. https://doi.org/10.1007/s41030-019-0091-0
Hahn, Beth, et al. "Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study." Pulmonary therapy vol. 5,1 (2019): 69-80. doi: https://doi.org/10.1007/s41030-019-0091-0
Hahn B, Stanford RH, Goolsby Hunter A, Essoi B, White J, Ray R. Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. Pulm Ther. 2019 Jun;5(1):69-80. doi: 10.1007/s41030-019-0091-0. Epub 2019 Apr 01. PMID: 32026428; PMCID: PMC6967076.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries